New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
10:07 EDTARIA, REPH, RSPP, NMM, HOLI, CSTM, CAB, BMRN, ATW, ATHL, AEO, ALE, SNSSOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ARIAD (ARIA) coverage transitioned with a Neutral at UBS... Allete (ALE) initiated with a Neutral at JPMorgan... American Eagle (AEO) initiated with a Fair Value at CRT Capital... Athlon Energy (ATHL) initiated with a Buy at Mizuho... Atwood Oceanics (ATW) initiated with a Hold at Deutsche Bank... BioMarin (BMRN) coverage transitioned with a Buy at UBS... Cabela's (CAB) initiated with a Neutral at Goldman... Constellium (CSTM) initiated with a Buy at Sterne Agee... Hollysys Automation (HOLI) initiated with a Buy at Goldman... Navios Maritime Partners (NMM) initiated with a Buy at Jefferies... RSP Permian (RSPP) initiated with a Buy at Mizuho... Recro Pharma (REPH) initiated with a Buy at Aegis... Sunesis (SNSS) initiated with a Buy at UBS.
News For ARIA;ALE;AEO;ATHL;ATW;BMRN;CAB;CSTM;HOLI;NMM;RSPP;REPH;SNSS From The Last 14 Days
Check below for free stories on ARIA;ALE;AEO;ATHL;ATW;BMRN;CAB;CSTM;HOLI;NMM;RSPP;REPH;SNSS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 30, 2014
15:31 EDTBMRNNotable companies reporting after market close
Subscribe for More Information
July 29, 2014
07:36 EDTNMMNavios Maritime Partners reports Q2 EPS 37c, may not compare to consensus 14c
Reports Q2 revenue $55.18M, consensus $57.47M.
July 25, 2014
10:07 EDTCABCabela's Sell rating removed at Off Wall Street Research (pre-open)
10:02 EDTCABOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:02 EDTCABOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:01 EDTRSPPRSP Permian agrees to acquire Midland Basin assets for $259M
Subscribe for More Information
08:07 EDTCSTMConstellium downgraded to Buy from Conviction Buy at Goldman
Goldman removed Constellium from the Conviction Buy List based on lack of near-term catalysts. Price target lowered to $36 from $40.
08:04 EDTCABCabela's upgraded to Buy from Neutral at DA Davidson
DA Davidson upgraded Cabela's to Buy citing stabilizing sales and compelling growth. Price target is $72.
07:47 EDTCABCabela's downgraded to Neutral from Buy at Monness Crespi
July 24, 2014
09:12 EDTREPHOpaleye Management reports 5.12% passive stake in Recro Pharma
Subscribe for More Information
08:08 EDTCABCabela's reaffirms FY guidance
Subscribe for More Information
08:07 EDTCABCabela's now sees Q3 EPS 80c-90c, consensus 90c
Subscribe for More Information
08:07 EDTCABCabela's reports Q2 EPS 61c, consensus 51c
Subscribe for More Information
July 23, 2014
18:34 EDTARIAOn The Fly: After Hours Movers
UP AFTER EARNINGS: Fortinet (FTNT), up 7.8%... Hanesbrands (HBI), up 5.4%... 8x8 (EGHT), up 5.1%... Infinera (INFN), up 4.9%... Facebook (FB), reverses and is now trading up 5.1% following second quarter earnings conference call. NOTABLE: Twitter (TWTR), up 1.7%, LinkedIn (LNKD), up marginally, and Yelp (YELP), up 1.6% after Facebook reports second quarter results. ALSO HIGHER: Spectranetics (SPNC), up 7.1% after receiving FDA clearance for atherectomy products, Turbo-Tandem and Turbo Elite... Ariad Pharmaceuticals (ARIA), up 7.1%... Jamba (JMBA), up 3.8% after Engaged Capital reports stake in the company and announced that they had discussions with management. DOWN AFTER EARNINGS: AT&T (T), down 1.2%... Angie's List (ANGI), down 16.4%... Tripadvisor (TRIP), down 11.5%... Orchids Paper (TIS), down 7.4%... Cirrus Logic (CRUS), down 6.6%... Cliffs Natural (CLF), down 1.2%... Teradyne (TER), down 4%. ALSO LOWER: Kandi Technologies (KNDI), down 3.8% after being mentioned negatively in a Seeking Alpha blog post.
13:59 EDTARIAARIAD rises 11.8% to $5.70
08:10 EDTBMRNBioMarin, Sarah Cannon Research UK collaborate on EMBRACA clinical study
BioMarin Pharmaceutical and Sarah Cannon Research UK announced a collaboration to enroll patients in an ongoing Phase 3 clinical trial of its PARP inhibitor, BMN 673, for the treatment of hereditary breast cancer with a BRCA mutation. This ongoing Phase 3 trial has recently been named EMBRACA. Sarah Cannon Research UK enrolled the first patient outside of the United States, expanding the trial internationally.
07:44 EDTBMRNBioMarin survey shows strong Vimizim demand, says Leerink
Subscribe for More Information
July 21, 2014
10:02 EDTRSPPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:04 EDTHOLIHollysys Automation awarded $8.28M contract by Shenyang - Dandong rail line
Subscribe for More Information
07:32 EDTRSPPRSP Permian upgraded to Buy from Accumulate at KLR Group
KLR Group upgraded RSP Permian to Buy citing the company's production growth and "superior" capital yield. The firm raised its price target for shares to $42 from $34.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use